Loading clinical trials...
Loading clinical trials...
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of the patients were randomized to CIS-GEM chemotherapy plus SIRT, and half of the patients were randomized to CIS-GEM alone.
This clinical study was a prospective, multicenter, randomized, controlled study evaluating SIR-Spheres Y-90 resin microspheres followed by cisplatin-gemcitabine (CIS-GEM) chemotherapy vs. CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic cholangiocarcinoma. Randomized patients were to be followed until death, withdrawal of consent, or until end of study.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Providence Health Care
Spokane, Washington, United States
Macquarie University Hospital
North Ryde, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hopital Beaujon
Clichy, France
CHU Dijon
Dijon, France
CHU de Grenoble
Grenoble, France
CHU Lyon - Hospital de la Croix-Rousse
Lyon, France
Institut Paoli Calmettes
Marseille, France
CHU Montpellier
Montpellier, France
Start Date
February 14, 2017
Primary Completion Date
April 29, 2021
Completion Date
April 29, 2021
Last Updated
May 9, 2025
89
ACTUAL participants
Cisplatin-gemcitabine
DRUG
Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
DEVICE
Lead Sponsor
Sirtex Medical
NCT06313203
NCT07337850
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06925516